This partnership validates D-PLEX100's commercial potential and provides a clear path to revenue with a well-capitalized partner. The key near-term catalyst is the FDA NDA acceptance milestone in August 2026, which triggers the second $15M payment. Traders should monitor FDA review progress and any PDUFA date updates for the Q1 2027 launch target.
Price Chart
Executive Summary
PolyPid entered into an exclusive License and Supply Agreement with Azurity Pharmaceuticals for the commercialization of D-PLEX100 in the U.S. and Canada. PolyPid receives a $15M upfront payment and a $15M near-term milestone upon FDA NDA acceptance (expected August 2026), with potential for up to ~$300M in additional milestone payments plus tiered mid-teen to mid-twenties royalties. Azurity will fund label expansion studies, while PolyPid retains manufacturing rights and ex-U.S./Canada commercial rights, marking a significant de-risking and value crystallization event for the company.
Key Facts
- $15M upfront payment due upon signing (July 17, 2026).
- $15M additional milestone payment due upon FDA NDA Filing Acceptance, expected August 2026.
- Up to ~$300M in additional regulatory, development, and sales-based milestone payments.
- Tiered royalties ranging from mid-teen to mid-twenties percentages on net sales.
- Azurity will fund clinical development for potential label expansion into additional SSI indications.
- U.S. launch targeted for Q1 2027.
- PolyPid retains global commercial rights outside U.S./Canada, manufacturing rights worldwide, and full ownership of its PLEX platform and Kynatrix technology.
- Agreement term is 20 years from the Effective Date.
Financial Impact
PolyPid to receive $30M in guaranteed upfront/near-term payments, up to ~$300M in additional milestones, and tiered mid-teen to mid-twenties royalties on U.S. and Canadian net sales.
Risk Factors
- FDA approval of D-PLEX100 is not guaranteed; a Complete Response Letter would delay or eliminate milestone and royalty payments.
- Commercial launch success depends on Azurity's execution and hospital adoption of a new SSI prophylaxis product.
- IIA (Israel Innovation Authority) restrictions may impose additional costs or limit technology transfer flexibility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-079808 |
| Document: ea029855901ex99-1.htm | 0001213900-26-079808 |
| Document: ea0298559-6k_polypid.htm | 0001213900-26-079808 |
| Document: 0001213900-26-079808-index-headers.html | 0001213900-26-079808 |
| Document: 0001213900-26-079808-index.html | 0001213900-26-079808 |
| Document: 0001213900-26-079808.txt | 0001213900-26-079808 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $4.90 | awaiting T+60 | — | $5.29 (+7.96%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | 6-K | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Oct 1, 2026 25d ago | Press Release | $5.37 | awaiting T+60 | — | $5.29 (−1.49%) |
Aug 12, 2026 10w ago | 6-K | $4.78 | awaiting T+60 | — | $5.29 (+10.67%) |
Aug 12, 2026 10w ago | 6-K | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Aug 12, 2026 10w ago | Press Release | $4.84 | awaiting T+60 | — | $5.29 (+9.30%) |
Jul 29, 2026 12w ago | 6-K | $4.08 $5.13 | ▲ +25.74% | ▲ +21.01% | $5.29 (+29.66%) |
Jul 21, 2026 14w ago | 6-K | $3.74 $4.83 | ▲ +29.14% | ▲ +26.30% | $5.29 (+41.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers